Palisade Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PALI research report →
Companywww.palisadebio.com
Palisade Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.
- CEO
- J. D. Finley
- IPO
- 2007
- Employees
- 8
- HQ
- Carlsbad, CA, US
Price Chart
Valuation
- Market Cap
- $321.12M
- P/E
- -16.06
- P/S
- 0.00
- P/B
- 3.05
- EV/EBITDA
- -7.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.79%
- ROIC
- -20.75%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-16,781,000 · -16.23%
- EPS
- $-0.30 · 97.06%
- Op Income
- $-18,056,000
- FCF YoY
- 11.04%
Performance & Tape
- 52W High
- $2.86
- 52W Low
- $0.53
- 50D MA
- $2.00
- 200D MA
- $1.66
- Beta
- 1.53
- Avg Volume
- 3.79M
Get TickerSpark's AI analysis on PALI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 11, 26 | Jones Mitchell Lawrence | other | 8,000 |
| Feb 11, 26 | Jones Mitchell Lawrence | other | 8,000 |
| Feb 12, 26 | Jones Mitchell Lawrence | sell | 1,989 |
| Feb 11, 26 | Finley John David | other | 13,333 |
| Feb 12, 26 | Finley John David | sell | 3,896 |
| Feb 11, 26 | Finley John David | other | 13,333 |
| Feb 9, 26 | Jones Mitchell Lawrence | other | 787,000 |
| Feb 9, 26 | Finley John David | other | 2,011,000 |
| Jan 16, 26 | Williams Donald Allen | buy | 5,000 |
| Jan 9, 26 | Williams Donald Allen | buy | 5,000 |
Our PALI Coverage
We haven't published any research on PALI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PALI Report →